LitCovid-sentences-v1  

PubMed:32150618 JSONTXT 34 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
TextSentencer_T1 0-174 Sentence denotes In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
TextSentencer_T2 175-186 Sentence denotes BACKGROUND:
TextSentencer_T3 187-319 Sentence denotes The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) first broke out in Wuhan (China) and subsequently spread worldwide.
TextSentencer_T4 320-392 Sentence denotes Chloroquine has been sporadically used in treating SARS-CoV-2 infection.
TextSentencer_T5 393-573 Sentence denotes Hydroxychloroquine shares the same mechanism of action as chloroquine, but its more tolerable safety profile makes it the preferred drug to treat malaria and autoimmune conditions.
TextSentencer_T6 574-763 Sentence denotes We propose that the immunomodulatory effect of hydroxychloroquine also may be useful in controlling the cytokine storm that occurs late-phase in critically ill SARS-CoV-2 infected patients.
TextSentencer_T7 764-861 Sentence denotes Currently, there is no evidence to support the use of hydroxychloroquine in SARS-CoV-2 infection.
TextSentencer_T8 862-870 Sentence denotes METHODS:
TextSentencer_T9 871-986 Sentence denotes The pharmacological activity of chloroquine and hydroxychloroquine was tested using SARS-CoV-2 infected Vero cells.
TextSentencer_T10 987-1117 Sentence denotes Physiologically-based pharmacokinetic models (PBPK) were implemented for both drugs separately by integrating their in vitro data.
TextSentencer_T11 1118-1321 Sentence denotes Using the PBPK models, hydroxychloroquine concentrations in lung fluid were simulated under 5 different dosing regimens to explore the most effective regimen whilst considering the drug's safety profile.
TextSentencer_T12 1322-1330 Sentence denotes RESULTS:
TextSentencer_T13 1331-1434 Sentence denotes Hydroxychloroquine (EC50=0.72 μM) was found to be more potent than chloroquine (EC50=5.47 μM) in vitro.
TextSentencer_T14 1435-1768 Sentence denotes Based on PBPK models results, a loading dose of 400 mg twice daily of hydroxychloroquine sulfate given orally, followed by a maintenance dose of 200 mg given twice daily for 4 days is recommended for SARS-CoV-2 infection, as it reached three times the potency of chloroquine phosphate when given 500 mg twice daily 5 days in advance.
TextSentencer_T15 1769-1781 Sentence denotes CONCLUSIONS:
TextSentencer_T16 1782-1877 Sentence denotes Hydroxychloroquine was found to be more potent than chloroquine to inhibit SARS-CoV-2 in vitro.